Quantifying HIV for Monitoring Antiretroviral Therapy in Resource-Poor Settings

Stevens, Wendy S.; Scott, Lesley E.; Crowe, Suzanne M.
April 2010
Journal of Infectious Diseases;4/15/2010 Supplement 1, Vol. 201, pS16
Academic Journal
There is increasing evidence to support the inability of CD4 cell count monitoring to predict virological failure in human immunodeficiency virus-infected individuals receiving antiretroviral therapy. There is renewed interest in improving access to viral load monitoring in resource-constrained regions to monitor adherence to treatment and to switch therapy. The field is rapidly changing as new technology platforms are made available for evaluation. This article presents an up to date summary of the assays available for viral load monitoring and suggests approaches for their implementation.


Related Articles

  • Performance of the PointCare NOW System for CD4 Counting in HIV Patients Based on Five Independent Evaluations. Bergeron, Michèle; Daneau, Géraldine; Ding, Tao; Sitoe, Nadia E.; Westerman, Larry E.; Stokx, Jocelijn; Jani, Ilesh V.; Coetzee, Lindi M.; Scott, Lesley; De Weggheleire, Anja; Boel, Luc; Stevens, Wendy S.; Glencross, Deborah K.; Peter, Trevor F.; Verhasselt, Bruno // PLoS ONE;Aug2012, Vol. 7 Issue 8, Special section p1 

    Introduction: Point-of-care (POC) CD4 testing can improve access to treatment by enabling decentralization and reducing patient loss-to-follow-up. As new POC CD4 technologies become available, their performance should be assessed before widespread deployment. This study reports the findings...

  • HIV-1 Plasma RNA level and CD4 cell count in a large urban HIV-1-infected patient population from 1997 to 2000. Shan, Hua; Piwowar-Manning, Estelle; Thompson, Richard E.; Brooks Jackson, J. // International Journal of STD & AIDS;Nov2003, Vol. 14 Issue 11, p740 

    We evaluated the change in plasma HIV-1 RNA level and CD4 cell counts in an HIV-1-infected population between 1997 and 2000. Both the mean and the median values of plasma HIV-1 RNA level decreased with time with the exception of 1998. The mean and medians for CD4 cell count appear to be fairly...

  • Coccidioidomycosis in Patients with HIV-1 Infection in the Era of Potent Antiretroviral Therapy. Masannat, Fares Y.; Ampel, Neil M. // Clinical Infectious Diseases;1/1/2010, Vol. 50 Issue 1, p1 

    Background. Coccidioidomycosis is a common opportunistic infection in human immunodeficiency virus type 1 (HIV-1)-infected individuals living in regions where coccidioidomycosis is endemic. However, there have been no studies on its incidence or clinical expression during the era of potent...

  • Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy. Negredo, Eugènia; Massanella, Marta; Puertas, Maria C.; Buzón, Maria J.; Puig, Jordi; Pérez-Alvárez, Núria; Pérez-Santiago, Josué; Bonjoch, Anna; Moltó, José; Jou, Antoni; Echeverría, Patricia; Llibre, Josep M.; Martínez-Picado, Javier; Clotet, Bonaventura; Blanco, Julià // Journal of Antimicrobial Chemotherapy (JAC);Oct2013, Vol. 68 Issue 10, p2358 

    Background Immune hyperactivation in immunodiscordant patients can induce residual HIV replication and limit CD4 T cell recovery. We assessed the impact of raltegravir intensification on CD4 T cell recovery and viral persistence. Methods We performed a randomized, controlled, pilot trial....

  • Emergence of Exhausted B Cells in Asymptomatic HIV-1-Infected Patients Naïve for HAART is Related to Reduced Immune Surveillance. Fogli, Manuela; Torti, Carlo; Malacarne, Fabio; Fiorentini, Simona; Albani, Melania; Izzo, Ilaria; Giagulli, Cinzia; Maggi, Fabrizio; Carosi, Giampiero; Caruso, Arnaldo // Clinical & Developmental Immunology;2012, p1 

    Alterations of B cell subpopulations have been described up to date as characterizing advanced stage of HIV-1 infection. However, whether such defects are relevant in subjects with a preserved number of CD4+ T cells (>350 cells/μL) is unclear. In a crosssectional study, we investigated if...

  • Tetracycline and T-cell Activation. Winslow, Dean L. // Infectious Disease Alert;Jun2010, Vol. 29 Issue 9, p105 

    CD4+ T cells were obtained from HIV-negative donors and HIV-positive patients receiving HAART with suppressed viremia. Using a single-cycle replication system and an X4 pseudovirus used to infect cells, minocycline, at concentrations from 0-50 ug/mL, demonstrated a dose-dependent reduction in...

  • Long-Term CD4 Cell Count Recovery among Thai Naive HIV-Infected Patients Initiating HAART at Low CD4 Cell Count. Romanee Chaiwarith; Parichart Salee; Wilai Kotarathitithum; Thira Sirisanthana; Khuanchai Supparatpinyo // Current HIV Research;May2009, Vol. 7 Issue 3, p340 

    CD4 T cell recovery after highly active antiretroviral therapy (HAART) has been reported mostly from developed countries. A retrospective cohort study was conducted among naïve HIV-infected patients initiating HAART between July 1, 2001 and December 31, 2004 at Chiang Mai University,...

  • Valganciclovir Reduces T Cell Activation in HIV-infected Individuals With Incomplete CD4+ T Cell Recovery on Antiretroviral Therapy. Hunt, Peter W.; Martin, Jeffrey N.; Sinclair, Elizabeth; Epling, Lorrie; Teague, Juli; Jacobson, Mark A.; Tracy, Russell P.; Corey, Lawrence; Deeks, Steven G. // Journal of Infectious Diseases;May2011, Vol. 203 Issue 10, p1474 

    Background. Elevated immune activation persists during treated human immunodeficiency virus (HIV) infection and is associated with blunted CD4 recovery and premature mortality, but its causes remain incompletely characterized. We hypothesized that asymptomatic cytomegalovirus (CMV) replication...

  • Novel strategies to treat antiretroviral-naive HIV-infected patients. Dunning, Jake; Nelson, Mark // Journal of Antimicrobial Chemotherapy (JAC);Oct2009, Vol. 64 Issue 4, p674 

    Although guidelines exist that provide recommended strategies for treating HIV-infected patients who are naive to antiretroviral therapy, treatment needs to be tailored to individual circumstances. Here we discuss the current recommendations and the evidence used in their development, along with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics